San Diego-based Trius Therapeutics is set to hit the markets today, after pricing its IPO last night. Trius will trade on the NASDAQ Global Market under the symbol TSRX. Trius, a biopharmaceuticals firm developing antibiotics, priced its IPO and increased the number of shares it would sell last night, dropping the offering price to $5.00 per share, and expanding the number of shares to 10,000,000. The firm had previously said it would sell 6,000,000 shares of its stock at between $12.00 and $14.00 per share. The IPO is being underwritten by Citigroup Global Markets, Piper Jaffray & Co., Canaccord Genuity Inc. and JMP Securities. The firm is venture backed by Sofinnova Venture Partners, InterWest Partners, Versant Ventures, Prism Venture Partners, and Kleiner Perkins Caufield & Byers.
Top NewsTuesday, August 3, 2010
Trius Therapeutics To Hit Markets Today In IPO